A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients
Phase 2
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002190
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
To explore the antiviral efficacy, tolerability and safety of saquinavir plus zidovudine plus lamivudine.
- Detailed Description
A total of 30 patients receive the triple drug regimen saquinavir plus zidovudine plus lamivudine until the completion of the analysis after at least 4 weeks of therapy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
Davies Med Ctr / c/o HIV Institute
🇺🇸San Francisco, California, United States
Columbia Presbyterian Med Ctr
🇺🇸New York, New York, United States
Pacific Oaks Med Group / Rsch & Scientific Investigation
🇺🇸Sherman Oaks, California, United States